Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.
How this was made
The 30-second read
Why it matters
The dosing start moves the program toward a pivotal proof‑of‑concept milestone, potentially reducing risk perception and supporting a future valuation uplift pending positive data.
Market read
Primary biotech news; relevance limited to investors tracking early‑stage antimicrobial therapies.
What to watch
Potential delays in enrollment or regulatory hurdles could dampen upside.
Background
Lakewood‑Amedex Biotherapeutics (NASDAQ: LABT) announced the first patient dosing in its Phase 2a Nu‑3 trial for mildly infected diabetic foot ulcers.
Ticker impact
First patient dosed in Phase 2a trial of Nu-3 for infected diabetic foot ulcers.
Modest upside as investors price in reduced clinical risk.
Early‑stage trial start is material but no data yet; market reaction typically limited until results.
Market effects
May boost interest in antimicrobial biotech sector and wound‑care therapeutics.
Limited to US biotech investors; no broader regional effect.
Minor, confined to niche biotech investors.
Counterpoint
Without data, the trial start could be over‑hyped; investors may wait for Phase 2b results.
Key entities
- companyLakewood‑Amedex Biotherapeutics Inc.
Clinical‑stage biotech developing Bisphosphocin® antimicrobial platform.
- productNu‑3
Topical antimicrobial gel targeting infected diabetic foot ulcers.
